Dr Heather Preston
Managing Director, TPG Biotech
Heather Preston, MD is Managing Director of TPG Biotech. Prior to joining TPG Biotech in May 2005, Dr. Preston spent two years at JP Morgan Partners where she focused on medical device and biotechnology venture capital investing.
Prior to JP Morgan Partners, Dr. Preston was an Entrepreneur-in-Residence with New Enterprise Associates. Dr. Preston has an undergraduate degree in biochemistry from the University of London and a medical degree from the University of Oxford.
After leaving Oxford, she completed a post-doctoral fellowship in molecular biology at the Dana Farber Cancer Institute, Harvard University. She completed her training in Internal Medicine at the Massachusetts General Hospital and then she sub-specialized in Gastroenterology and Hepatology at U.C.S.F.
During her academic career, she was the recipient of a Fulbright Scholarship, a Fulbright Cancer Research Scholarship, a Harlech Scholarship and a Science and Engineering Research Council Post-doctoral Fellowship Award. After leaving academic medicine, she spent five years at McKinsey & Co. in New York, where she was a leader of their pharmaceutical and medical products consulting practice.
She advised large pharmaceutical companies and biotechnology companies on critical strategic issues such as R&D portfolio prioritization, M&A opportunities, new technology acquisitions, new product launches and product growth strategies.
Dr. Preston co-founded, and is the CEO of Virobay Inc., a biotechnology company which is seeking to develop new therapies for the treatment of Hepatitis C Virus (HCV).
Dr. Preston serves on the boards of Albireo, Alder Biotherapeutics, Axcan Pharma, Virobay Inc. and VLST Inc.; and is an observer on the boards of Aerie Pharmaceuticals, FoldRx, Kémia and Macrogenics